CM
JAZZ icon

CM Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

CM Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$2.48M – 75
2025
Q1 		$2.48M Buy
20,000
+5,000
+33% +$652K 2.49% 13
2024
Q4 		$1.85M Sell
15,000
-5,000
-25% -$589K 1.65% 30
2024
Q3 		$2.23M Buy
20,000
+7,500
+60% +$822K 1.78% 25
2024
Q2 		$1.33M Hold
12,500
– – 1.22% 35
2024
Q1 		$1.51M Buy
+12,500
New +$1.53M 1.26% 32

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

CM Management's JAZZ Position: Q2 2025 in Review

CM Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 20,000 shares — an estimated $2.48M sold.

CM Management first reported a position in JAZZ in Q1 2024 and held it in 5 quarters. The position peaked at $2.48M in Q1 2025. 502 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • CM Management reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • CM Management sold 20,000 Jazz Pharmaceuticals shares in Q2 2025, an estimated $2.48M.
  • CM Management first reported a position in Jazz Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • CM Management's Jazz Pharmaceuticals position peaked at $2.48M in Q1 2025.
  • 502 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on CM Management's 13F filing for Q2 2025, filed 12 Aug 2025.